DPP-4 Inhibitor Composition for Aortic Valve Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and therapies fail to effectively prevent or treat aortic valvular calcification, a condition that contributes to various cardiovascular complications and increased mortality, with DPP-4 expression levels being elevated during calcification but not previously targeted for inhibition.
Innovation Solution
A pharmaceutical composition containing a DPP-4 inhibitor, such as sitagliptin, is administered to inhibit the activity of DPP-4, reducing osteoblast metastasis and differentiation, thereby preventing or treating aortic valvular calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DPP-4 inhibitor is administered to inhibit osteoblast differentiation and prevent aortic valvular calcification, then the effectiveness of preventing/treating calcification is improved, but the expression level of DPP-4 in the cardiovascular system may be reduced
Solution Approach 1:
The patent changes the parameter of DPP-4 activity level by administering DPP-4 inhibitors to achieve therapeutic effect while managing the expression level trade-off
2Adaptability or versatility
If current treatments and therapies are used for aortic valvular calcification, then existing therapeutic approaches are maintained, but the effectiveness in preventing or treating calcification is insufficient
Solution Approach 1:
The patent introduces a new therapeutic parameter (DPP-4 inhibition) that differs from existing treatments, achieving improved effectiveness by targeting a different biochemical pathway involved in calcification
Data Source
Figure 1
Figure 2a~2c
Figure 3~4
AI summary
The present invention relates to a composition for preventing or treating valve calcification, containing a dipeptidyl peptidase-4 (DPP-4) inhibitor. The DPP-4 inhibitor according to the present invention may include all of what can inhibit the expression of DPP-4 nucleotides or the activity of DPP-4 proteins, wherein: DPP-4 antibodies, sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, Anagliptin, evogliptin, Berberine, Diprotin, or Lupeol; DPP-4 mRNA anti-sense nucleotides, aptamers, small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA), or RNA interference (RNAi); or the like can be used.